AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04028973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single then dual task situation
Description: Firstly, the participants have to perform the fatiguing task in simple task condition (control condition, i.e., muscle contraction alone). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same fatiguing task with a concomitant memory cognitive task (i.e. dual-task condition).
Study NCT04028973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single then dual task situation
Description: Firstly, the participants have to perform the fatiguing task in simple task condition (control condition, i.e., muscle contraction alone). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same fatiguing task with a concomitant memory cognitive task (i.e. dual-task condition).
Study NCT04028973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual then single task situation
Description: Firstly, the participants have to perform the fatiguing task in dual-task condition (i.e. muscle fatiguing contraction with a concomitant memory cognitive task). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same muscle fatiguing task without a concomitant memory cognitive task (i.e. control condition).
Study NCT04028973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual then single task situation
Description: Firstly, the participants have to perform the fatiguing task in dual-task condition (i.e. muscle fatiguing contraction with a concomitant memory cognitive task). Secondly, few days later (between 3 and 7 days later), the participants have to perform the same muscle fatiguing task without a concomitant memory cognitive task (i.e. control condition).
Study NCT01267864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoclopramide
Description: 10mg IVSS
Study NCT01267864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: 30g IVSS
Study NCT01267864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Description: 1gm IVSS
Study NCT05192928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ripple Health Smart Pill Cap
Description: The device is a smart medical device created to allow physicians to have better access to patient compliance data, and intervene on the patient's health through the use of a text message, phone call, or email.
Study NCT04576286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Holmium versus Bipolar en bloc transurethral resection
Description: After obtaining informed consent, patients will be randomized with a 1:1 ratio using sealed envelopes that will be prepared by the department's ethical committee into 2 groups, group 1 represent the Holmium en bloc resection procedure while group 2 represents bipolar en bloc resection. Patients will be blinded to the type of intervention as well as the data collector and the statistician.~Intervention: all procedures will be done by an expert surgeon who performed over 50 cases of en bloc urinary bladder tumor resection with each energy source. In group A, Holmium en bloc resection procedure will be done under either general or spinal anesthesia, using a Holmium laser device (Cyber Ho, Quanta device, Milano, Italy). We will use a 30-40-watt power, 1-2 joules and 20-30 MHz frequency for Group A and bipolar en bloc resection for Group B. A 550 nm flexible laser fiber will be used in group A and a bipolar resection loop for group B.
Study NCT04576286 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium versus Bipolar en bloc transurethral resection
Description: After obtaining informed consent, patients will be randomized with a 1:1 ratio using sealed envelopes that will be prepared by the department's ethical committee into 2 groups, group 1 represent the Holmium en bloc resection procedure while group 2 represents bipolar en bloc resection. Patients will be blinded to the type of intervention as well as the data collector and the statistician.~Intervention: all procedures will be done by an expert surgeon who performed over 50 cases of en bloc urinary bladder tumor resection with each energy source. In group A, Holmium en bloc resection procedure will be done under either general or spinal anesthesia, using a Holmium laser device (Cyber Ho, Quanta device, Milano, Italy). We will use a 30-40-watt power, 1-2 joules and 20-30 MHz frequency for Group A and bipolar en bloc resection for Group B. A 550 nm flexible laser fiber will be used in group A and a bipolar resection loop for group B.
Study NCT03821233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZW49
Description: * Dose Escalation: ZW49 administered intravenously at dose levels determined by the SMC~* Expansion: MTD or RD identified in the dose-escalation part of the study
Study NCT02152137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efatutazone
Description: Given PO
Study NCT02152137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT03433911 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemBloc
Description: Treatment with FemBloc for women who desire permanent birth control (female sterilization)
Study NCT03433911 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic bilateral tubal sterilization
Description: Laparoscopic bilateral tubal sterilization for women who desire permanent birth control (female sterilization)
Study NCT01295645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Description: 0.5 mg/kg by vein (IV) 3 times a week for 4 weeks.
Study NCT01295645 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Cidofovir
Description: Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
Study NCT04244578 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Active tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
Study NCT04244578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Sham tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), but the current will be applied for 30 s and will be ramped down without the participants awareness.
Study NCT04244578 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS will be delivered to parieto-occipital areas for five consecutive days. tDCS will be delivered by a battery driven, direct current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands. The electrodes will be placed on the left (anodal) and right (cathodal) parieto-occipital areas, PO7 and PO8 position according to the 10-20 international EEG system for electrode placement. Stimulation intensity will be set at 1 milliampere (mA), but the current will be applied for 30 s and will be ramped down without the participants awareness.
Study NCT00543933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iNO administered
Description: iNO at 40 ppm through a non-rebreather mask for 5 minutes
Study NCT04651686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative three-dimensional reconstruction and intraoperative protection of bronchial artery
Description: All patients underwent chest enhanced CT examination with 64 slice spiral CT before operation. The bronchial artery was reconstructed by Mimics software. The bronchial artery was protected according to the preoperative three-dimensional reconstruction image during the lymph node dissection
Study NCT04497103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: The traditional therapy included immersing the hand in paraffin for 10 min; soft massaging with a moisturizing gel for 5 min; passive mobilization of the wrist, MP, PIP, and DIP joints; active/passive ROM and stretching exercises; strengthening exercises (done in static mode initially and progressed in the second month to dynamic strengthening using elastic bands); desensitizing sensory stimulation of hypertrophic scars, occupational therapy.
Study NCT04497103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: The traditional therapy included immersing the hand in paraffin for 10 min; soft massaging with a moisturizing gel for 5 min; passive mobilization of the wrist, MP, PIP, and DIP joints; active/passive ROM and stretching exercises; strengthening exercises (done in static mode initially and progressed in the second month to dynamic strengthening using elastic bands); desensitizing sensory stimulation of hypertrophic scars, occupational therapy.
Study NCT04497103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xbox kinect
Description: The traditional plus Xbox Kinect games were related to five target activities determined according to the person-centered analysis results were chosen for each patient.
Study NCT04497103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: task oriented training
Description: The traditional plus the target activities involved training with the materials (clothes, spoons, pencils, buttons, rope, etc) needed for the activity as well as Velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
Study NCT05049564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: keyhole microneurosurgery
Description: microsurgical clipping via keyhole approach
Study NCT05049564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional microneurosurgery
Description: microsurgical clipping via conventional craniotomy
Study NCT05049564 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular coiling
Description: endovascular coiling via femoral approach
Study NCT00386217 — intervention group
Intervention type: BEHAVIORAL
Intervention: Telephone Survey
Description: Telephone interview, about 90 minutes, covering demographic information, medical information, health-related quality of life, emotional distress, and stress related to interrupted childbearing.
Study NCT03775265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03775265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy of Bladder
Description: Undergo a bladder biopsy
Study NCT03775265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy of Bladder
Description: Undergo a bladder biopsy
Study NCT03775265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT03091634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xue-fu-zhu-yu capsule
Description: participants are given to 6 xue-fu-zhu-yu capsule per time, twice a day. The duration is 7 weeks
Study NCT03775265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03775265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or MRI
Study NCT03775265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or MRI
Study NCT03775265 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystoscopy
Description: Undergo a cystoscopy
Study NCT03775265 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: Undergo a cystoscopy
Study NCT03091634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: xue-fu-zhu-yu capsule simulated agent
Description: participants are given to 6 xue-fu-zhu-yu capsule simulated agent per time, twice a day. The duration is 7 weeks
Study NCT03782272 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enterade
Description: enterade® (an amino acid-based oral rehydration solution \[AA-ORS\]) is a medical food product that consists of oral rehydration salts, natural flavor, steviol (sweetener), purified water, and a blend of amino acids that drive the uptake of water and electrolytes.
Study NCT03782272 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a placebo solution containing natural flavor, steviol (sweetener), and purified water.
Study NCT03801148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg dexlansoprazole capsules manufactured at TPC
Description: Dexlansoprazole delayed-release capsules.
Study NCT03801148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg dexlansoprazole capsules manufactured at TOB
Description: Dexlansoprazole delayed-release capsules.
Study NCT03775265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study NCT03791112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-16350
Description: BPI-16350 capsules administered orally
Study NCT03801148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60 mg dexlansoprazole capsules manufactured at TPC
Description: Dexlansoprazole delayed-release capsules.
Study NCT01997606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: use of Purotex treated bedding covers
Description: Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types. The active probiotics are placed inside of millions of capsules and are introduced during the textile production. These human friendly bacteria remain non-active until friction force is created between the mattress/pillow and the sleeper's body. Under the friction force a small part of the capsules is opened and probiotics become active. They saturate the bacterial capacity of the textile and by doing so, reduce the risk of dust mite allergen development and growth of molds and harmful bacteria. The patients will apply the covers around their mattress and around their pillow. On top of these covers the patients will apply their own fitted sheet and pillowcase (which they will change every 4 weeks).
Study NCT01997606 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01153711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744
Description: 10 mcg solution for oral inhalation
Study NCT01153711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 400 mg tablet
Study NCT02910752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLAM+PBSC
Description: Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
Study NCT03287713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxygen therapy
Description: conventional nasal prongs vs nasal high flow oxygen during Pulmonary Rehabilitation in Interstitial Lung Disease.
Study NCT01143142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based tailoring system
Description: Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will produce messages for a two-page educational brochure based on participants' responses to survey questions. Only the intervention group will receive this brochure.
Study NCT01143142 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-based tailoring system
Description: Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will produce messages for a two-page educational brochure based on participants' responses to survey questions. Only the intervention group will receive this brochure.
Study NCT00047190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given PO
Study NCT00911976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xience V coronary stent
Description: The Xience V stent will be implanted in aortocoronary saphenous vein bypass graft lesions
Study NCT00047190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01205932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: Daily dose: 5mg/day (5mg, once daily) for 34 to 35 days (±4 days)
Study NCT01205932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: Daily dose: 7.5mg/day (7.5mg, once daily) for 34 to 35 days (±4 days)
Study NCT01205932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (BAY59-7939)
Description: Daily dose: 10mg/day (10mg, once daily) for 34 to 35 days (±4 days)
Study NCT01205932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: daily dose: 40mg/day (20mg each, twice daily) for 6 to 7 days (±2 days)
Study NCT02262026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 125 mg AZD0530
Description: Randomized to receive 125 mg of AZD0530
Study NCT01606813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard care
Study NCT01606813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Physician Counseling
Description: Primary Care Physician (PCP) will review a goal setting worksheet for weight loss with the participant and then collaboratively set a goal for weight loss.
Study NCT02262026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg AZD0530
Description: Randomized to receive 125 mg of AZD0530
Study NCT01606813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Physician Counseling
Description: Primary Care Physician (PCP) will review a goal setting worksheet for weight loss with the participant and then collaboratively set a goal for weight loss.
Study NCT01606813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral and access to an internet weight control program
Description: Participants will receive a login and password for the weight loss website. The website will encourage patients to set a new weight goal every 3 months and work towards a total weight loss goal of 10%. Patients will also receive an email prompt each week alerting them to new content and reminding them to check-in to the website to report their weight, intake and activity.
Study NCT01606813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief follow up email notes from PCPs
Description: Patients will receive a biweekly email from their primary care physician on how they are doing with their weight loss.
Study NCT00913289 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: adipose tissue derived stromal cells
Description: dosage
Study NCT05485818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose
Description: 12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.25 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
Study NCT05485818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Middle Dose
Description: 12±4 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：0.5 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
Study NCT05485818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose
Description: 12±4 hours after PCI: 2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection），Day2-Day7 after PCI：2.0 ug/kg Recombinant Human Thymosin β4 （intravenous injection）
Study NCT05485818 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 subjects will be randomly assigned to the placebo for 7 days
Study NCT01290003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-Tazobactam and Amikacin
Description: Inj Piperacillin-Tazobactam 50 mg/Kg/dose 12 hourly IV X 3 days (6 doses) Inj Amikacin 15 mg/kg/dose 24 hourly IV X 3 days (3 doses)
Study NCT02747394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Working Memory Training
Study NCT02747394 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Working Memory Training
Study NCT03758391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flipped Classroom education
Description: Fellows will receive GI/Bilirubin education in a flipped classroom format.
Study NCT01303796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapacitabine
Description: Oral sapacitabine capsules
Study NCT01303796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: Decitabine intravenous
Study NCT01303796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine intravenous
Study NCT02262026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50 mg AZD0530
Description: Randomized to receive 50 mg of AZD0530
Study NCT02262026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg AZD0530
Description: Randomized to receive 50 mg of AZD0530